Jul 31, 2017 — Accelerate Diagnostics, Inc. announced today the addition of Romney Humphries, PhD, D(ABMM), M(ASCP) to its executive management team as Chief Scientific Officer.
Jun 15, 2017 — Accelerate Diagnostics, Inc. showcased new data presented at ASM Microbe 2017 on the potential clinical and workflow benefits of faster susceptibility results using the Accelerate Pheno™ system and Accelerate PhenoTest™ BC kit.
May 30, 2017 — Accelerate Diagnostics, Inc. today announced that new data from 11 healthcare institutions covering more than 1,200 samples will be presented at the upcoming annual meeting of the American Society for Microbiology – ASM Microbe in New Orleans, LA.
May 15, 2017 — Accelerate Diagnostics, Inc. (Nasdaq:AXDX) announced the closing of its previously announced underwritten public offering of 2,750,000 shares of its common stock today, upsized from the original share offering of 2,500,000 shares of common stock, at a previously disclosed public offering price of $28.85 per share. The gross proceeds to Accelerate Diagnostics from the offering are approximately $79.3 million before deducting underwriting commissions and discounts, and estimated offering expenses payable by the company.
May 03, 2017 — Accelerate Diagnostics, Inc. today announced preliminary financial results for the quarter ending March 31, 2017 including signed customer evaluation contracts covering 169 instruments, 22 additional instruments converted into revenue generating placements, and revenue growth exceeding 325% of the same period in the prior year.
Apr 18, 2017 — Accelerate Diagnostics, Inc. announced today it will host a conference call on Wednesday, May 3rd, 2017 to discuss its first quarter 2017 financial results and commercial progress.
Feb 28, 2017 — Accelerate Diagnostics filed Fourth Quarter and Full Year 2016 financial results today. Access them directly on our website in the SEC filings section of our Investors page or through the Securities and Exchange Commission’s (SEC) website.
Feb 24, 2017 — Accelerate Diagnostics, Inc. (Accelerate) today announced that the U.S. Food and Drug Administration has granted the de novo request to market the Accelerate Pheno™ system and Accelerate PhenoTest™ BC kit for identification and antibiotic susceptibility testing of pathogens directly from positive blood culture samples. The blood culture kit is indicated for susceptibility testing of specific pathogenic bacteria commonly associated with bacteremia, the leading cause of sepsis.
Nov 18, 2016 — This week members from the healthcare community worldwide aim to increase awareness about #AntimicrobialResistance led by the World Health Organization and the Centers for Disease Control and Prevention. Accelerate Diagnostics stands with them to share the importance of reducing the misuse and overuse of antibiotics which has become a worldwide public health concern. Learn more […]
Oct 21, 2016 — TUCSON, Ariz., Oct. 21, 2016 (GLOBE NEWSWIRE) — Accelerate Diagnostics, Inc. announced today it will report third-quarter 2016 financial results on Wednesday, November 9, 2016. President and Chief Executive Officer, Lawrence Mehren, joined by Steve Reichling, Chief Financial Officer, will host a conference call to review the results at 4:15 p.m. ET. The quarterly financial […]